Company intelligence / Profile preview

B ELITE

San Diego, California, United Statesbelite.org ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Belite Bio’s lead candidate Tinlarebant (LBS‑008), an oral small molecule targeting RBP4, is in Phase 3 clinical trials for Stargardt disease type 1 and geographic atrophy. The drug has shown target specificity and potency in clinical studies. LBS‑009 is a preclinical candidate targeting metabolic diseases including NAFLD/NASH and type 2 diabetes

Therapeutic areas: RheumatologyOphthalmologyGastroenterologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on B ELITE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B ELITE.

Explore the full profile